LOPROX (ciclopirox) by Eurofarma Laboratórios is protein synthesis inhibitors [moa]. First approved in 1982.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
LOPROX (ciclopirox) is a topical antifungal cream approved in 1982 that works by inhibiting fungal protein synthesis. It is used to treat various fungal and bacterial skin infections. The product targets dermatological conditions requiring topical antimicrobial therapy.
With LOE approaching and moderate competitive pressure (30%), the brand team is likely in consolidation or optimization mode with stable but not expanding headcount.
Protein Synthesis Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers
Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer
Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis
Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children
Worked on LOPROX at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LOPROX offers exposure to mature product management and defensive commercial strategy in a competitive dermatology market. Career value lies in execution excellence, market access challenges, and generic/competitive response strategies rather than innovation-driven growth.